Stablepoint Partners’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.3M Buy
31,144
+176
+0.6% +$60.2K 1.56% 6
2026
Q1
$10.9M Sell
30,968
-331
-1% -$118K 1.62% 6
2025
Q4
$10.2M Buy
31,299
+270
+0.9% +$85.6K 1.6% 11
2025
Q3
$8.76M Buy
31,029
+1,139
+4% +$330K 1.39% 11
2025
Q2
$8.35M Buy
29,890
+990
+3% +$280K 1.42% 11
2025
Q1
$9M Buy
28,900
+6,431
+29% +$1.9M 1.63% 7
2024
Q4
$5.86M Buy
22,469
+135
+0.6% +$40.1K 1.07% 23
2024
Q3
$7.2M Buy
22,334
+1,860
+9% +$608K 1.31% 15
2024
Q2
$6.81M Buy
20,474
+9,087
+80% +$2.67M 1.32% 13
2024
Q1
$3.24M Buy
11,387
+1,959
+21% +$573K 0.66% 55
2023
Q4
$2.72M Buy
+9,428
New +$2.57M 0.7% 51

Other funds holding AMGN

Stablepoint Partners's AMGN Position: Q2 2026 in Review

Stablepoint Partners increased its Amgen (AMGN) stake by 0.57% in Q2 2026, buying an estimated $60.2K and bringing the position to 31,144 shares worth $11.3M. The position accounts for 1.56% of the portfolio, ranked #6.

Stablepoint Partners first reported a position in AMGN in Q4 2023 and has held it in 11 quarters since. 577 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Stablepoint Partners held 31,144 shares of Amgen worth $11.3M as of Q2 2026.
  • Stablepoint Partners bought 176 Amgen shares in Q2 2026, an estimated $60.2K.
  • Amgen made up 1.56% of Stablepoint Partners's portfolio in Q2 2026, its #6 holding.
  • Stablepoint Partners first reported a position in Amgen in Q4 2023 and has held it in 11 quarters since.
  • 577 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Stablepoint Partners's 13F filing for Q2 2026, filed 9 Jul 2026.